Cancer is the second leading cause of death in the world. Given that cancer is a highly individualized disease, predicting the best chemotherapeutic treatment for individual patients can be difficult. Ex vivo models such as mouse patient-derived xenografts (PDX) and organoids are being developed to predict patient-specific chemosensitivity profiles before treatment in the clinic. Although promising, these models have significant disadvantages including long growth times that introduce genetic and epigenetic changes to the tumor. The zebrafish xenograft assay is ideal for personalized medicine. Imaging of the small, transparent fry is unparalleled among vertebrate organisms. In addition, the speed (5–7 days) and small patient tissue requirements (100–200 cells per animal) are unique features of the zebrafish xenograft model that enable patient-specific chemosensitivity analyses.

癌症是世界上第二大死亡原因。鉴于癌症是一种高度个体化的疾病，预测个体患者的最佳化疗治疗可能很困难。离体正在开发模型，例如小鼠患者衍生的异种移植物 (PDX) 和类器官，以在临床治疗前预测患者特异性化学敏感性曲线。尽管很有希望，但这些模型具有显着的缺点，包括长的生长时间，这会给肿瘤带来遗传和表观遗传变化。斑马鱼异种移植试验是个性化医疗的理想选择。小型透明鱼苗的成像在脊椎动物生物中是无与伦比的。此外，速度（5-7 天）和小患者组织要求（每只动物 100-200 个细胞）是斑马鱼异种移植模型的独特特征，可以进行患者特异性化学敏感性分析。